YOU ARE HERE: LAT HomeCollectionsLung Cancer

Lung Cancer

September 17, 2007 | From Times wire reports
Guidelines released Monday by the American College of Chest Physicians indicate that at present lung cancer screening with CT scanning and other methods is generally not warranted outside of studies. The researchers conclude that screening with CT imaging or certain sputum tests does not reduce lung cancer deaths, even in high-risk groups such as heavy smokers.
May 15, 2006 | From Times wire reports
A significant proportion of women with newly diagnosed lung cancer had normal lung function tests, U.S. researchers have reported. The finding means that women who lack symptoms of lung disease should not automatically be considered free of lung cancer risk, they said in the May issue of the journal Chest.
October 12, 2006 | From Bloomberg News
Genentech Inc. on Wednesday won U.S. approval to market its Avastin colon cancer drug as a treatment for lung cancer, potentially reviving sales growth for the biotechnology company's second-biggest product. The Food and Drug Administration cleared Avastin to treat the most common form of lung cancer in combination with chemotherapy, the South San Francisco-based company said.
March 7, 2007 | Thomas H. Maugh II, Times Staff Writer
Only five months after a major study recommended routine use of CT scans to detect lung cancer, a second study recommends the opposite, concluding that the scans do not save lives. Both studies found an estimated 10-year survival rate as high as 90% among patients whose cancers were detected early. But the new study, reported today in the Journal of the American Medical Assn., found no difference in the number of lung cancer deaths between the screened group and a control group.
June 2, 2008 | From Times Wire Reports
A simple blood test may be able to detect lung cancer in its early stages, which would represent a promising strategy to improve survival rates, researchers said. The two-year survival rate averages only about 15%, mainly because the disease, which kills 1.3 million people globally a year, is often diagnosed in advanced stages. Preliminary findings of a study presented in Chicago at the annual meeting of the American Society of Clinical Oncology suggest that a specific genetic profile for lung cancer is present in the blood and can be detected with 88% accuracy.
April 21, 2001 | Associated Press
Gun control advocate Sarah Brady said Friday night that she has been battling lung cancer for at least a year. Brady, 59, said on CNN's "Larry King Live" that the original tumor that doctors discovered in her lung has disappeared but two spots remain in the same lung. She said she had non-small cell carcinoma--a slow-moving form of cancer. Brady, a lifelong smoker, said she is still smoking, though not as much. She heads the Center to Prevent Handgun Violence.
Lung cancer death rates appear finally to be dropping among Americans under 45, according to a new study that provides evidence of the effectiveness of anti-smoking campaigns in controlling the country's most common fatal cancer. The federal study, published today in the Journal of the National Cancer Institute, found the decline especially striking among white men. But a drop has also occurred among black men and white and black women since the mid-1970s.
January 8, 2007 | From Times wire reports
Testing five genes in tumors might help doctors determine which patients with lung cancer are likely to fare best after surgery and which need the strongest treatments, according to a new study. A five-gene test distinguished patients who would survive almost 3 1/2 years after diagnosis from those who would live about half as long, said researchers led by Pan-Chyr Yang, an oncologist at National Taiwan University Hospital in Taipei, in last week's New England Journal of Medicine.
August 14, 2006 | From Times wire reports
Researchers say they have developed a test that can predict with near certainty whether the most common form of lung cancer will return after surgery. The new test could save tens of thousands of lives every year by letting doctors prescribe more aggressive treatments for patients whose cancers are likely to reappear, said the team of scientists who developed it at Duke University. Called the Lung Metagene Predictor and described in the Aug.
December 14, 2006 | From Bloomberg News
Genentech Inc.'s Avastin medicine prolonged the lives of patients with a form of recurrent or advanced lung cancer by two months, according to a study to be published today in the New England Journal of Medicine. The median survival time of patients who received Avastin in addition to chemotherapy was 12.3 months, compared with 10.3 for those getting just the chemicals, researchers said.
Los Angeles Times Articles